Patents by Inventor Hideki Kubota
Hideki Kubota has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9376449Abstract: The present invention relates to indole carboxamide compounds of formula (I) or a salt thereof wherein R2, R3, R4, R6, R7, R8, R51 and R52 have the meanings as indicated herein, and are MT1 and/or MT2 receptor agonists useful for treating and/or preventing urological diseases.Type: GrantFiled: July 9, 2013Date of Patent: June 28, 2016Assignee: Astellas Pharma Inc.Inventors: Takatoshi Kanayama, Hideki Kubota, Shunichiro Matsumoto, Tomoyuki Saito, Takafumi Shimizu, Naoto Katoh, Shigeo Matsui
-
Patent number: 9260445Abstract: The present invention relates to indole carboxamide compounds of formula (I) or a salt thereof wherein R2, R3, R4, R6, R7, R8, R51 and R52 have the meanings as indicated herein, and are MT1 and/or MT2 receptor agonists useful for treating and/or preventing urological diseases.Type: GrantFiled: July 9, 2013Date of Patent: February 16, 2016Assignee: Astellas Pharma Inc.Inventors: Takatoshi Kanayama, Hideki Kubota, Shunichiro Matsumoto, Tomoyuki Saito, Takafumi Shimizu, Naoto Katoh, Shigeo Matsui
-
Patent number: 9150575Abstract: A compound represented by the general formula (I) or a pharmacologically acceptable salt thereof has an excellent LCAT-activating effect and is useful as an active ingredient in a therapeutic or prophylactic agent for arteriosclerosis, arteriosclerotic heart disease, coronary heart disease (including heart failure, myocardial infarction, angina pectoris, cardiac ischemia, cardiovascular disturbance, and restenosis caused by angiogenesis), cerebrovascular disease (including stroke and cerebral infarction), peripheral vascular disease (including diabetic vascular complications), dyslipidemia, hypo-HDL-cholesterolemia, or renal disease, particularly, an anti-arteriosclerotic agent, wherein R is an optionally substituted aryl group or an optionally substituted heteroaryl group.Type: GrantFiled: December 10, 2014Date of Patent: October 6, 2015Assignee: Daiichi Sankyo Company, LimitedInventors: Hideki Kobayashi, Nobuyuki Ohkawa, Daisuke Takano, Hideki Kubota, Toshio Onoda, Toshio Kaneko, Masami Arai, Naoki Terasaka
-
Publication number: 20150203505Abstract: [Problem] To provided a compound which is useful as an MT1 and/or MT2 receptor agonist. [Means for Solution] The present inventors have conducted studies on MT1 and/or MT2 receptor agonists, and have found that an indole carboxamide compound has an MT1 and/or MT2 receptor agonistic action, thereby completing the present invention. The indole carboxamide compound of the present invention has the MT1 and/or MT2 receptor agonistic action as well as a low CNS penetration, and therefore, it can be used as an agent for preventing and/or treating urological diseases; in one embodiment, lower urinary tract symptoms; in another embodiment, urine storage symptom, in another embodiment, urinary incontinence; in a still another embodiment, stress urinary incontinence; and the like.Type: ApplicationFiled: July 9, 2013Publication date: July 23, 2015Applicant: Astellas Pharma Inc.Inventors: Takatoshi Kanayama, Hideki Kubota, Shunichiro Matsumoto, Tomoyuki Saito, Takafumi Shimizu, Naoto Katoh, Shigeo Matsui
-
Publication number: 20150152102Abstract: A compound represented by the general formula (I) or a pharmacologically acceptable salt thereof has an excellent LCAT-activating effect and is useful as an active ingredient in a therapeutic or prophylactic agent for arteriosclerosis, arteriosclerotic heart disease, coronary heart disease (including heart failure, myocardial infarction, angina pectoris, cardiac ischemia, cardiovascular disturbance, and restenosis caused by angiogenesis), cerebrovascular disease (including stroke and cerebral infarction), peripheral vascular disease (including diabetic vascular complications), dyslipidemia, hypo-HDL-cholesterolemia, or renal disease, particularly, an anti-arteriosclerotic agent, wherein R is an optionally substituted aryl group or an optionally substituted heteroaryl group.Type: ApplicationFiled: December 10, 2014Publication date: June 4, 2015Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Hideki Kobayashi, Nobuyuki Ohkawa, Daisuke Takano, Hideki Kubota, Toshio Onoda, Toshio Kaneko, Masami Arai, Naoki Terasaka
-
Patent number: 8785462Abstract: The present invention provides a compound which enhances the production of erythropoietin. The present invention provides a compound represented by formula (1): [wherein, R1: formula (1A): [wherein, R4 and R5: H, halogen, or alkyl; R6: H, halogen, alkyl, or the like; R7: substitutable hydroxyalkyl, substitutable hydroxyhalo alkyl, substitutable alkoxyalkyl, or the like; substituent group ?: oxo, hydroxy, amino, or the like; ring Q1: a monocyclic heterocyclic group; ring Q2: a monocyclic hydrocarbon ring group, or a monocyclic heterocyclic group; ring Q3: a monocyclic hydrocarbon ring group, or a monocyclic heterocyclic group; X: a single bond, methylene, ethylene, or the like]; R2: alkyl, or methylsulfanyl; and R3: H, or methyl], or the like.Type: GrantFiled: October 20, 2010Date of Patent: July 22, 2014Assignee: Daiichi Sankyo Company, LimitedInventors: Takeshi Kuribayashi, Hideki Kubota, Naoki Tanaka, Takeshi Fukuda, Takashi Tsuji, Riki Goto
-
Patent number: 8674096Abstract: Substituted imidazo[1,5-a]quinoxalin-4-ones are useful as phosphodiesterase 9 inhibitors.Type: GrantFiled: November 27, 2012Date of Patent: March 18, 2014Assignee: Astellas Pharma Inc.Inventors: Hiroyuki Kaizawa, Mari Sugita, Hidenori Azami, Ryushi Seo, Takaho Nomura, Satoshi Yamamoto, Hirofumi Yamamoto, Kazuyuki Tsuchiya, Hideki Kubota, Kazunori Kamijo
-
Patent number: 8357688Abstract: Substituted imidazo[1,5-a]quinoxalin-4(5H)-ones are useful as PDE9 inhibitors.Type: GrantFiled: March 4, 2010Date of Patent: January 22, 2013Assignee: Astellas Pharma Inc.Inventors: Hiroyuki Kaizawa, Mari Sugita, Hidenori Azami, Ryushi Seo, Takaho Nomura, Satoshi Yamamoto, Hirofumi Yamamoto, Kazuyuki Tsuchiya, Hideki Kubota, Kazunori Kamijo
-
Patent number: 8314240Abstract: [Object] A compound which is useful as an EP1 receptor antagonist is provided. [Means for Solution] The present inventors investigated EP1 receptor antagonists, and confirmed that a compound having a sulfonamide structure, in which the nitrogen atom of the sulfonamide structure is substituted with 2-fluoropropyl group, 3-fluoro-2-methylpropyl group or the like, has a potent EP1 receptor antagonistic action, thereby completing the present invention. The sulfonamide compound of the present invention has a potent EP1 receptor antagonistic action and can be used as an agent for preventing and/or treating a lower urinary tract symptom or the like.Type: GrantFiled: June 22, 2009Date of Patent: November 20, 2012Assignee: Astellas Pharma Inc.Inventors: Hideki Kubota, Issei Tsukamoto, Kazunori Kamijo, Koji Kato, Yuta Fukuda, Hidenori Azami
-
Publication number: 20120220609Abstract: The present invention provides a compound which enhances the production of erythropoietin. The present invention provides a compound represented by formula (1): [wherein, R1: formula (1A): [wherein, R4 and R5: H, halogen, or alkyl; R6: H, halogen, alkyl, or the like; R7: substitutable hydroxyalkyl, substitutable hydroxyhalo alkyl, substitutable alkoxyalkyl, or the like; substituent group ?: oxo, hydroxy, amino, or the like; ring Q1: a monocyclic heterocyclic group; ring Q2: a monocyclic hydrocarbon ring group, or a monocyclic heterocyclic group; ring Q3: a monocyclic hydrocarbon ring group, or a monocyclic heterocyclic group; X: a single bond, methylene, ethylene, or the like]; R2: alkyl, or methylsulfanyl; and R3: H, or methyl], or the like.Type: ApplicationFiled: October 20, 2010Publication date: August 30, 2012Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Takeshi Kuribayashi, Hideki Kubota, Naoki Tanaka, Takeshi Fukuda, Takashi Tsuji, Riki Goto
-
Patent number: 8114886Abstract: The present invention relates to a novel compound having an effect of inhibiting production/secretion of ?-amyloid protein. The present invention provides a compound represented by the general formula (1): or a salt thereof, or a solvate of the compound or the salt; and a medicament comprising thereof.Type: GrantFiled: April 7, 2006Date of Patent: February 14, 2012Assignee: Daiichi Sankyo Company, LimitedInventors: Satoru Miyauchi, Hideki Kubota, Kayoko Motoki, Masayuki Ito
-
Publication number: 20110319385Abstract: [Problem] Provided is a compound which has a PDE9-inhibiting action and is useful as an active ingredient for an agent for treating and/or preventing storage dysfunction, voiding dysfunction, and bladder/urethral diseases, and the like. [Means for Solution] The present inventors have investigated a compound which has a PDE9-inhibiting action and is useful as an active ingredient for an agent for treating and/or preventing storage dysfunction, voiding dysfunction, and bladder/urethral diseases, and the like, and thus, have found that an imidazoquinoxaline compound or a triazoloquinoxaline compound has a PDE9-inhibiting action, thereby completing the present invention. The imidazoquinoxaline compound or the triazoloquinoxaline compound of the present invention has a PDE9-inhibiting action and can be used as an agent for preventing and/or treating storage dysfunction, voiding dysfunction, and bladder/urethral diseases, and the like.Type: ApplicationFiled: March 4, 2010Publication date: December 29, 2011Applicant: Astellas Pharma Inc.Inventors: Hiroyuki Kaizawa, Mari Sugita, Hidenori Azami, Ryushi Seo, Takaho Nomura, Satoshi Yamamoto, Hirofumi Yamamoto, Kazuyuki Tsuchiya, Hideki Kubota, Kazunori Kamijo
-
Publication number: 20110201616Abstract: [Object] A compound which is useful as an EP1 receptor antagonist is provided. [Means for Solution] The present inventors investigated EP1 receptor antagonists, and confirmed that a compound having a sulfonamide structure, in which the nitrogen atom of the sulfonamide structure is substituted with 2-fluoropropyl group, 3-fluoro-2-methylpropyl group or the like, has a potent EP1 receptor antagonistic action, thereby completing the present invention. The sulfonamide compound of the present invention has a potent EP1 receptor antagonistic action and can be used as an agent for preventing and/or treating a lower urinary tract symptom or the like.Type: ApplicationFiled: June 22, 2009Publication date: August 18, 2011Applicant: Astellas Pharma Inc.Inventors: Hideki Kubota, Issei Tsukamoto, Kazunori Kamijo, Koji Kato, Yuta Fukuda, Hidenori Azami
-
Patent number: 7973078Abstract: A compound that can be used as an agent for treating a disease associated with an EP1 receptor, in particular a lower urinary tract symptom. It was confirmed that a sulfonamide compound having an amide structure and characterized by a chemical structure in which a carbon atom in the amide bonds to the N atom in sulfonamide through lower alkylene, or a salt thereof, has a potent EP1 receptor antagonistic activity, accomplishing the present invention. Since the sulfonamide compound of the present invention or a pharmaceutically acceptable salt thereof has a potent EP1 receptor antagonistic activity, it is useful as an agent for treating a disease associated with an EP1 receptor, in particular, a lower urinary tract symptom.Type: GrantFiled: August 9, 2007Date of Patent: July 5, 2011Assignee: Astellas Pharma Inc.Inventors: Hideki Kubota, Susumu Toda, Issei Tsukamoto, Yuta Fukuda, Ryutaro Wakayama, Kazuki Ono, Toru Watanabe, Hidenori Azami
-
Publication number: 20110112103Abstract: The present invention provides compounds which promote erythropoietin production.Type: ApplicationFiled: April 21, 2009Publication date: May 12, 2011Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Takeshi Kuribayashi, Hideki Kubota, Takeshi Fukuda, Rieko Takano, Takashi Tsuji, Koji Sasaki, Naoki Tanaka
-
Patent number: 7932271Abstract: Provided is a compound capable of inhibiting production or secretion of ? amyloid protein. A compound represented by the following formula (1): (wherein, R1 represents a heterocyclic group which may have a substituent, R2 represents a cyclic hydrocarbon group which may have a substituent or a heterocyclic group which may have a substituent, R3 represents a cyclic hydrocarbon group which may have a substituent or a heterocyclic group which may have a substituent, R4 represents a hydrogen atom or a C1-6 alkyl group, and X represents —S—, —SO— or —SO2—); an N-oxide or S-oxide thereof; a salt thereof; or a solvate thereof; and a medicament containing any of them.Type: GrantFiled: June 29, 2004Date of Patent: April 26, 2011Assignee: Daiichi Pharmaceutical Co., Ltd.Inventors: Hideki Kubota, Takanori Yasukouchi, Satoru Miyauchi, Kayoko Motoki, Masanori Saito, Hitoshi Iimori
-
Publication number: 20100168136Abstract: A compound having activity to inhibit production and/or secretion of ?-amyloid protein, and is useful for prevention and/or treatment of various diseases associated with abnormal production and/or secretion of ?-amyloid protein, the compound represented by the general formula (I): [wherein, R1 represents a C1-C6 alkyl group which may have 1 to 6 halogen atoms as substituent groups, a C2-C6 alkenyl group which may have 1 to 6 halogen atoms as substituent groups, or a C3-C7 cycloalkyl group which may have 1 to 6 halogen atoms as substituent groups; R2 represents a 6-membered nitrogen-containing monocyclic aromatic heterocyclic group having 1 to 3 substituent groups, or a 9- or 10-membered nitrogen-containing bicyclic heterocyclic group having 1 to 4 substituent groups; Z1, Z2 and Z3 each independently represent a hydrogen atom, a halogen atom or a cyano group; and n represents 0, 1 or 2], salts thereof, or solvates thereof.Type: ApplicationFiled: March 11, 2010Publication date: July 1, 2010Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Hitoshi Iimori, Hideki Kubota, Satoru Miyauchi, Kayoko Motoki
-
Publication number: 20090312328Abstract: [Object] A compound that can be used as an agent for treating a disease associated with an EP1 receptor, in particular, a lower urinary tract symptom. [Means for Solution] It was confirmed that a sulfonamide compound having an amide structure and characterized by a chemical structure in which a carbon atom in the amide bonds to the N atom in sulfonamide through lower alkylene, or a salt thereof, has a potent EP1 receptor antagonistic activity, accomplishing the present invention. Since the sulfonamide compound of the present invention or a pharmaceutically acceptable salt thereof has a potent EP1 receptor antagonistic activity, it is useful as an agent for treating a disease associated with an EP1 receptor, in particular, a lower urinary tract symptom.Type: ApplicationFiled: August 9, 2007Publication date: December 17, 2009Applicant: Astellas Pharma Inc.Inventors: Hideki Kubota, Susumu Toda, Issei Tsukamoto, Yuta Fukuda, Ryutaro Wakayama, Kazuki Ono, Toru Watanabe, Hidenori Azami
-
Publication number: 20090149439Abstract: The present invention relates to a novel compound having an effect of inhibiting production/secretion of ?-amyloid protein. The present invention provides a compound represented by the general formula (1): or a salt thereof, or a solvate of the compound or the salt; and a medicament comprising thereof.Type: ApplicationFiled: April 7, 2006Publication date: June 11, 2009Applicant: Daiichi Sankyo Company LimitedInventors: Satoru Miyauchi, Hideki Kubota, Kayoko Motoki, Masayuki Ito
-
Publication number: 20080227785Abstract: This invention relates to an anti-dementia agent which uses a BEC 1 potassium channel inhibitor as the active ingredient. It was proved that the BEC 1 potassium channel inhibitor has an action to improve learning disorder and is useful as a preventive or therapeutic agent for diseases, preferably dementia, in which the BEC 1 potassium channel is considered to be concerned. Illustratively, it was confirmed by an in vivo test that the BEC 1 potassium channel inhibitor has an action to improve learning disorder. Also, it was found that a compound having 2,4,6-triamino-1,3,5-triazine has a BEC 1 potassium channel inhibitory action.Type: ApplicationFiled: February 6, 2008Publication date: September 18, 2008Applicant: Astellas Pharma Inc.Inventors: Hideki Kubota, Takeshi Suzuki, Masanori Miura, Eiichi Nakai, Kiyoshi Yahiro, Akira Miyake, Shinobu Mochizuki, Kazuhiro Nakatou